SRTCX1003 manufacturers
- SRTCX1003
-
- $1520.00
-
2026-05-11
- CAS:1203480-86-7
- Purity:
- Supply Ability: 10g
|
| | SRTCX1003 Basic information |
| | SRTCX1003 Chemical Properties |
| | SRTCX1003 Usage And Synthesis |
| Description | SRTCX1003 is a SIRT1 activator which suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. | | Uses | SRTCX1003 is an orally active SIRT1 activator. SRTCX1003 suppresses inflammatory responses[1]. | | in vivo | SRTCX1003 (3-100 mg/kg; oral; once) decreases LPS (HY-D1056)-stimulated TNFα and IL-12p40 production in mice inflammation model[1]. | Animal Model: | Male BALB/c mice, LPS-induced inflammation mouse model[1] | | Dosage: | 3, 10, 30 and 100 mg/kg | | Administration: | Oral, 60 minutes prior to LPS administration | | Result: | Dose-dependently reduced LPS-stimulated TNFα and IL-12p40 production. |
| | References | [1] Yang H, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. DOI:10.1371/journal.pone.0046364 |
| | SRTCX1003 Preparation Products And Raw materials |
|